

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

UNITED STATES DISTRICT COURT  
EASTERN DISTRICT OF CALIFORNIA

KENNETH GLASS, individually, and on behalf of all others similarly situated,

Plaintiff,

v.

GLOBAL WIDGET, LLC d/b/a HEMP BOMBS,

Defendant.

No. 2:19-cv-01906-MCE-KJN

**MEMORANDUM AND ORDER**

Plaintiff Kenneth Glass (“Plaintiff”) alleges, both on his own behalf and on behalf of others similarly situated, a nationwide collective action claim against Defendant Global Widget, LLC d/b/a Hemp Bombs (“Defendant”) on grounds that hemp cannabidiol (“CBD”) products sold by Defendant were both misbranded and illegal. Plaintiff’s operative First Amended Complaint (“FAC”) alleges eight different causes of action made on various grounds, including breach of express warranty, breach of the implied warranty of merchantability, unjust enrichment, and fraud, as well as for violations of various state consumer protection, unfair competition, and false advertising.<sup>1</sup>

///

---

<sup>1</sup> Counts V through VII of the FAC allege California statutory violations; Count VIII is for violations of Florida’s Deceptive and Unfair Practices Act.

1 Presently before the Court is Defendant's Motion to Dismiss and/or Strike  
2 pursuant to Federal Rules of Civil Procedure 12(b)(1), 12(b)(6) and 12(f). Alternatively,  
3 Defendant requests that the Court either dismiss or stay the matter pursuant to the  
4 primary jurisdiction doctrine pending imminent regulatory action by the United States  
5 Food and Drug Administration ("FDA") regarding CBD products.

6 As set forth below, because the Court concludes that a stay is indeed appropriate  
7 under the circumstances of this matter, Defendant's Motion (ECF No. 22) will be  
8 GRANTED in that regard but is otherwise DENIED,<sup>2</sup> without prejudice to refile once the  
9 stay in this case has been lifted.

### 11 BACKGROUND<sup>3</sup>

12  
13 CBD is a naturally occurring phytocannabinoid found in certain strains of hemp,  
14 and according to Plaintiff is a highly sought-after substance with medicinal properties  
15 used to treat anxiety, insomnia, depression, diabetes, PTSD and chronic pain. CBD can  
16 be ingested in numerous ways, including inhalation by smoke or vapor, as an aerosol  
17 spray into the cheek, and by mouth. In addition, food and beverage items can be  
18 infused with CBD as an alternative way of taking the substance. The production, sale  
19 and distribution of CBD has becoming a booming business that "is gaining in popularity  
20 among consumers with the legal CBD market projected to surpass \$23 billion in annual  
21 U.S. Sales by 2023," according to Forbes Magazine. FAC, ECF No. 19, ¶ 12.

22 Defendant, a Florida corporation with a principal place of business in Tampa,  
23 Florida, manufactures, sells, and globally distributes Hemp Bombs-branded products,  
24 and is responsible for the advertising, marketing and packaging of CBD-infused edibles,

25  
26 <sup>2</sup> Because the Court believes that a stay in this matter is indicated pending further action by the  
27 FDA, and since such action may profoundly change just what claims Plaintiff can assert, the Court need  
28 not address Defendant's remaining challenges to the sufficiency of Plaintiff's pleadings at this time and  
declines to do so.

<sup>3</sup> Unless otherwise noted, this section is drawn, at times verbatim, from the allegations of the FAC.

1 capsules, oils and vape products. According to the FAC, Plaintiff, a California resident,  
2 purchased many of Defendant's Hemp Bombs CBD products throughout 2019, most  
3 recently in June of 2019,<sup>4</sup> when he bought two packages of Hemp Bombs Gummies  
4 from a gas station in Wheatland, California. He states that he relied on Defendant's  
5 labeling representations concerning the quantities of CBD his purchases contained, only  
6 to later discover through testing that the products contained anywhere between 7 and  
7 82.3 percent less CBD than stated on the label.

8 According to Plaintiff, Defendant also made specific representations on its website  
9 that CBD was legal to sell in the United States, when in fact it is not. Id. at ¶¶ 22-23.  
10 Plaintiff contends that he and other class members would not have purchased  
11 Defendant's products, or paid as much for those products, had they known the products  
12 were mislabeled and falsely advertised. Id. at ¶ 29.

13 Defendant, in requesting a stay of these proceedings, claims that the FDA is  
14 poised to issue CBD regulations soon that should provide substantial clarification and  
15 guidance concerning the issues raised by this lawsuit. It alleges that the FDA conducted  
16 a public hearing on CBD in 2019, and thereafter appointed an agency task force along  
17 with a public docket for comment. Def.'s Mot, ECF No. 22-1, 10:15-17. On  
18 November 25, 2019, the FDA issued a consumer update on CBD entitled "What you  
19 Need to Know (And What We're Working to Find Out) About Products Containing  
20 Cannabis or Cannabis-derived Compounds, Including CBD." The agency stated it  
21 "recognizes the significant public interest" in such compounds, and "is working on  
22 answering these questions through ongoing efforts including feedback from a recent  
23 FDA hearing and information and data gathering through a public docket." See Def.'s  
24 Mot., 10-15-11:2, n.4 and citations contained therein.<sup>5</sup> The FDA further advised that the  
25 agency "is evaluating the regulatory frameworks that apply to certain [CBD products] that

26 <sup>4</sup> While the FAC indicates these last purchases occurred in July 2019, Plaintiff indicates in his  
27 Opposition to the instant Motion that this was a scrivener's error, with the correct time being June of 2019.

28 <sup>5</sup> Whether or not the FDA considers CBD to be a dietary supplement remains in dispute according  
to Defendant, since the Agency has to date issued mixed messages on the issue.

1 are intended for non-drug uses, including whether and/or how the FDA might consider  
2 updating its regulations, as well as whether potential legislation might be appropriate.”

3 Id.

4 The FDA’s efforts to provide further guidance to the public continue. On  
5 January 13, 2020, the Chairman of the House Agricultural Committee, Collin Peterson  
6 (D-MN), introduced bi-partisan legislation (H.R. 5587) that would allow hemp-derived  
7 CBD (and substances containing CBD) to be marketed as dietary supplements, and  
8 would require the FDA to immediately develop regulations to that effect.<sup>6</sup> Defendant  
9 also claims that regulatory efforts with important potential ramifications for this case are  
10 underway in California, where the California Assembly has passed A.B. 228, which  
11 would declare that foods (including dietary supplements), beverages and cosmetics  
12 made with industrial hemp should not be considered adulterated, as Plaintiff alleges.  
13 See id. at 11:7-10, citing FAC at ¶¶ 24-25. Defendant claims the Bill is currently pending  
14 before the California Senate.

15  
16 **STANDARD**  
17

18 It is well-established that “[a] district court ‘has broad discretion to stay  
19 proceedings as an incident to its power to control its own docket’ in an effort to promote  
20 judicial economy.” DeMartini v. Johns, 693 F. App’x 534, 538 (9th Cir. 2017) (quoting  
21 Clinton v. Jones, 520 U.S. 681, 706-707 (1997)); see also Landis v. North Am. Co.,  
22 299 U.S. 248, 254-55 (1936) (“[T]he power to stay proceedings is incidental to the power  
23 inherent in every court to control the dispositions of the cases on its docket with  
24 economy of time and effort for itself, for counsel, and for litigants. How this can be done  
25 calls for the exercise of judgment, which must weigh competing interests and maintain  
26 an even balance.”).

27 ///

28 <sup>6</sup> See <https://www.congress.gov/bill/116th-congress/house-bill/5587>.

1 In determining the propriety of a stay, courts look to issues of judicial economy  
2 and the prejudice to either party that may result if the stay is granted or denied. CMAX,  
3 Inc. v. Hall, 300 F.2d 265, 268 (9th Cir. 1962). Whether to issue a stay in this regard is a  
4 decision necessarily relegated to the court's discretion. Nken v. Holder, 556 U.S. 418,  
5 433-34 (2009).

6  
7 **ANALYSIS**

8  
9 On May 22, 2020, the Northern District of California issued its decision in  
10 Colette v. CV Sciences, Inc., No. 2:19-cv-10227-VAP-JEM(x), 2020 WL 2739861.<sup>7</sup>  
11 Colette, like the present matter, is a class action relating to the marketing and sale of  
12 CBD products. Also similar to the case at bar, the plaintiff in Colette argues that she  
13 would not have purchased products containing CBD if she knew they were not legally  
14 sold in the United States. Id. at \*1.<sup>8</sup>

15 The Northern District ultimately stayed the litigation pending before it, citing the  
16 so-called "primary jurisdiction" doctrine. Importantly, the court noted that its case was  
17 one of several cases already pending that relate to the marketing and sale of CBD  
18 products, including four similar cases in the Northern and Central Districts alone. Id.

19 "The primary jurisdiction doctrine allows courts to stay proceedings, or to dismiss  
20 a complaint without prejudice pending the resolution of an issue within the special  
21 competence of an administrative agency." Clark v. Time Warner Cable, 523 F.3d 1110,  
22 1114 (9th Cir. 2008). It "is a prudential doctrine under which courts may, under  
23 appropriate circumstances, determine that the initial decisionmaking responsibility  
24 should be performed by the relevant agency rather than the courts." GCB

25 \_\_\_\_\_  
26 <sup>7</sup> While decided on May 22, 2020, after briefing in this matter concluded on March 16, 2020,  
27 defense counsel brought Colette to the Court's attention by filing a Notice of Supplemental Authority  
28 attaching the decision on June 3, 2020. Plaintiff's counsel has filed nothing in response to that  
submission.

<sup>8</sup> It does not appear, however, that the Colette case contained evidence of misbranding like this  
matter.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.